I question the motivation of these so-called "analysts" who upgrade or downgrade stocks. Are they truly objective? Do they or their firm hold a position, long or short, in the stock they "analyze" and recommend, one way or the other? Can we really take them seriously? I find it best to make your own analysis based upon accounting reports and projections. Based upon my own analysis, and I have been doing this longer than the average age of these "analysts", and for what it's worth, MT is grossly undervalued. I project a price of $35. within 12 to 18 months.
You say you have a lot of analytical smarts, but you give no basis for your projection of $35 per share. At that price the yield would be barely over 5%, way below MT's peers in the medical and hotel sectors.
The way is see it, MT will get to something in the $18-20 range, where the yield will be 9-10%. At that point I plan to take profits, so please enlighten me as to why it should go higher!
A yield projection of 5% in 12-18 months based on a price of $35. assuming no change in dividend payout will be exceptional and in line with the projected yields of other REITs in similar industries compared with a below 4% yield in long term T-bonds, 18 months from now.
Don't ask me how I know this because I'm afraid to tell you.
If the Hilton thing works out fine but explain your thoughts on that buy please. I think MT has done a lot better job in restructuring than PAH has.One guy downgrades MT and the stock drops 11/16. What a joke. I would much rather go with MT than PAH.By the way. Has PAH decided on a dividend yet or is it still quarter to quarter.Also MT can always raise the dividend Val.You didn't sell MT to buy PAH did you? Just a thought.